Zentavion

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zentavion

What is Zentavion?

Zentavion is a therapeutic agent developed for the management of specific conditions within the field of oncology. It belongs to a class of medications designed to interact with cellular pathways that contribute to the growth and spread of malignant cells. By targeting these specific biological mechanisms, the medication aims to stabilize or reduce the progression of the disease.

Mechanism of Action

The active components in Zentavion work at a molecular level to inhibit certain proteins or enzymes that are overactive in specific types of cancer. When these proteins are blocked, the signaling pathways that tell cancer cells to divide and multiply are interrupted. This process can lead to a slowing of tumor growth and, in some instances, a reduction in tumor size.

Therapeutic Intent

The primary objective of treatment with Zentavion is to provide a systemic approach to disease management. It is often utilized when traditional or first-line interventions require additional support or when the specific genetic profile of a tumor suggests that a targeted approach may be beneficial for the patient's clinical outlook.

Clinical Application

In a clinical setting, Zentavion is used to address chronic or advanced stages of illness. Healthcare providers determine its suitability based on a comprehensive evaluation of the patient's medical history, the characteristics of the condition, and the results of diagnostic testing. The focus of its use is to improve the management of the underlying pathology while maintaining the patient's overall health status.

What side effects are possible with Zentavion?

Possible Side Effects and Safety Information

The official safety characteristics of Azithromycin (Zentavion) outline specific patterns of adverse reactions and special safety considerations derived from clinical data and postmarketing surveillance. The effects are grouped by the physiological system affected and classified by frequency as determined by regulatory authorities.

General Adverse Reactions by Classification

The most frequently documented adverse reactions are those affecting the Gastrointestinal System. Reactions classified as Common in official labeling include the occurrence of diarrhea, nausea, abdominal pain, and vomiting, alongside headache. Reactions classified as Uncommon span multiple system-organ classes, including the Nervous System (dizziness, vertigo) and Skin (rash, pruritus).

Serious Adverse Reaction Warnings

Official regulatory documents highlight several areas of serious adverse potential. Azithromycin has been associated with prolongation of the QT interval, which carries a risk of developing a serious cardiac arrhythmia known as Torsades de pointes. Severe, and sometimes fatal, hepatotoxicity, including hepatic failure, has also been documented. Furthermore, serious cutaneous reactions, such as Stevens-Johnson Syndrome, and Clostridioides difficile-associated diarrhea are officially listed as potential serious adverse events.

Contextual and Population Safety Notes

The label identifies specific safety constraints for certain patient groups. Older adults may be more susceptible to cardiac arrhythmias. A risk of Infantile Hypertrophic Pyloric Stenosis (IHPS) is noted following use in neonates (treatment up to 42 days of life). The medicine is Contraindicated in individuals with a history of cholestatic jaundice or hepatic dysfunction associated with prior Azithromycin use. Allergic symptoms may recur soon after initial symptomatic treatment is discontinued, a pattern linked to the drug's prolonged tissue half-life.

Overdose and Emergency Response

Overdose and When to Seek Help

In the event of suspected exposure to higher than recommended doses of Zentavion (Azithromycin), immediate medical attention must be sought. If the individual has collapsed, experienced a seizure, or cannot be awakened, contact emergency services or a national poison control helpline right away.

Documented Overdose Manifestations and Risks

Adverse reactions documented following an overdose are generally similar to those seen at normal therapeutic doses. These manifestations primarily involve severe gastrointestinal distress, including nausea, vomiting, and diarrhoea, along with abdominal discomfort. Some regulatory labeling also notes reversible loss of hearing as a possible symptom associated with macrolide overdose.

The official prescribing information highlights a serious potential complication: treatment with Azithromycin can lead to prolongation of the cardiac repolarisation and QT interval. This cardiac effect is associated with a risk of developing a potentially fatal irregular heart rhythm known as torsades de pointes, a factor that requires careful clinical consideration in all overdose situations.

Mandated Emergency Response

Regulators state that management of a Zentavion overdose requires general symptomatic treatment and supportive measures. There is no specific antidote documented in the official prescribing information. The administration of medicinal charcoal is one of the procedural measures officially described for overdose management.

Therapeutic Uses of Zentavion

Zentavion (Azithromycin) is a therapeutic option commonly used to help with the management of bacterial illnesses. Its clinical use is relevant in contexts marked by increased discomfort or tension and assists with managing the clusters of symptoms that interfere with daily functioning. The medication is relevant across multiple infection types.


Easing Acute Respiratory and Dermatological Distress

This medication is applied in clinical settings that involve acute or unstable symptom patterns, primarily used for managing bacterial infections associated with symptoms related to systemic imbalance (like fever) and symptoms related to inflammatory or irritative states (such as severe cough, chest congestion, or localized redness and pain). It is commonly used across conditions presenting with acute episodes, including community-acquired pneumonia, bacterial sinusitis, acute otitis media, and uncomplicated skin structure infections. The medication provides supportive relief when symptoms interfere with routine activities and contributes to improved comfort during symptomatic periods.

“It helps address symptom clusters that may become intense or disruptive in acute infection scenarios.”

Support for Targeted and Recurrent Conditions

Zentavion is also considered relevant in targeted clinical scenarios, including the management of certain sexually transmitted infections (STIs) like Chlamydia trachomatis and is relevant for easing symptoms linked to organ-specific functional stress (such as certain eye infections). Furthermore, it may be part of symptomatic management in conditions like COPD or bronchiectasis, where it may assist with managing the severity of recurrent manifestations. This application supports patients during episodes of heightened discomfort and supports general well-being during symptomatic phases.

Quick Fact: Relief for Acute Distress Zentavion is commonly used to manage the symptoms of infection across the respiratory tract, skin, and genitourinary system, and is used for managing symptoms that become more disruptive during flare-ups in chronic lung conditions.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Zentavion (Azithromycin) is a prescription medicine whose population-eligibility rules are strictly defined by regulatory authorities to ensure safe use.

Populations for Whom Use is Contraindicated

Use is absolutely prohibited in patients with a known hypersensitivity or allergy to Azithromycin, any macrolide, or any ketolide antibiotic. It is also contraindicated in patients with a history of cholestatic jaundice or hepatic dysfunction previously associated with the use of Azithromycin.

Eligibility and Conditional Use Rules

Population Group Regulatory Status
Severe Liver Disease Not recommended (e.g., Child-Pugh Class C).
Infants Safety and effectiveness are not established for most uses in patients under 6 months of age.
Cardiovascular Risk Use requires caution in patients with known QT interval prolongation or other proarrhythmic conditions.
Severe Kidney Impairment Use requires caution in patients with severe renal impairment (GFR < 10 mL/min), though mild-to-moderate impairment does not require adjustment.
Myasthenia Gravis Use requires caution due to the risk of exacerbating muscle weakness.
Pregnancy/Lactation Permitted only if the benefit outweighs the potential risk; caution is advised during breastfeeding.

Eligibility extends to adults and children six months of age and older for approved indications. Specific dosage forms, such as tablets, are typically restricted for children weighing under 45 kg.

What should I know about interactions with other medicines?

The official regulatory documents for Zentavion detail specific interaction patterns with other medicines and products. The most significant interaction is the pharmacodynamic risk of QT prolongation. Co-administration with other medicines known to prolong the QT interval, such as Class IA and Class III antiarrhythmics, cisapride, and pimozide, is restricted due to the documented potential for an additive effect, increasing the risk of Torsades de pointes.

Concurrent use of Azithromycin with ergot derivatives is officially not recommended due to the theoretical possibility of ergotism.

In terms of pharmacokinetic effects, Azithromycin does not significantly interact with the hepatic Cytochrome P450 system. However, it may increase the plasma concentration of certain co-administered medicines that are P-glycoprotein substrates, including Digoxin and Colchicine. This interaction requires close clinical monitoring.

Interaction with oral anticoagulants, such as Warfarin, may potentiate their effects; therefore, procedural constraints require careful monitoring of prothrombin time during co-administration.

Regarding specific products, Antacids containing aluminum or magnesium hydroxide reduce the peak serum concentration (Cmax) of Azithromycin. To manage this effect, the two products must not be taken simultaneously, and administration should be separated by an interval of at least two hours. Lastly, systemic exposure to Azithromycin is officially documented to be significantly increased in individuals with severe renal impairment.

Mechanism of Action

Interference with Bacterial Protein Synthesis

Zentavion, containing Azithromycin, exerts its effect by interfering with the essential molecular machinery of susceptible bacteria. The molecule functions as a protein synthesis inhibitor by directly binding to the 23S ribosomal RNA (rRNA) component of the bacterial 50S ribosomal subunit . This interaction occurs near the ribosomal exit tunnel. This interference arrests the process of bacterial translation and the elongation of polypeptide chains.


Functional Consequence: Bacteriostasis

The molecular blockade results in a bacteriostatic effect, which inhibits bacterial growth and replication. This mechanism is supported by the drug's ability to accumulate in high concentrations within host immune cells (e.g., phagocytes). The resulting suppression of microbial proliferation permits the host immune system to engage in the clearance of the non-replicating bacterial population. The mechanism is constrained by bacterial resistance processes, including active drug efflux and enzymatic modification of the ribosomal target site.

Dosage and Administration Information

How to Use Zentavion: Administration Guidelines

Zentavion is prescribed for the prevention of nausea and vomiting associated with highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC). It is intended for use as part of a combination regimen that includes a corticosteroid and a 5-HT3 antagonist (anti-emetic).


Route and Dosing Schedule

The route of administration is oral. The hard capsule must be swallowed whole and can be taken with or without food. The standard regimen is administered over three consecutive days:

Day Dose Timing
Day 1 125 mg Administer one hour before the start of chemotherapy.
Day 2 80 mg Administer once daily in the morning (if no chemotherapy).
Day 3 80 mg Administer once daily in the morning (if no chemotherapy).

Special Administration Conditions

Age-Specific Rules: The three-day dosing schedule applies to adults and adolescents (aged 12 through 17 years). The safety and efficacy in children under 12 years of age have not been established.

Co-administered Drugs: Zentavion may interact with other medications. The recommended dose of co-administered dexamethasone (a corticosteroid) must be reduced to account for this interaction. For example, for adults undergoing HEC, the dexamethasone dose is reduced on Day 1 (from 20 mg to 12 mg) and Days 2-4 (from 16 mg to 8 mg).

Contraceptives: The efficacy of hormonal contraceptives may be reduced during Zentavion treatment and for 28 days following the last dose. Patients must use alternative, non-hormonal back-up methods during treatment and for two months following the last dose.

Recent Clinical Evidence

Research on Zentavion (Azithromycin) for acute infections, such as those in the respiratory tract, ears, and skin, is based on short-term Randomized Controlled Trials (RCTs). These studies typically compared Zentavion to other antibiotics, with researchers monitoring outcomes related to patient-reported outcomes describing perceived discomfort and clinical change measurements in the observed populations. For Community-Acquired Pneumonia, research measured overall clinical change, while trials for ear and sinus infections tracked changes in symptom intensity within a short follow-up interval.

Research examined Zentavion in the context of specific infections of the genitourinary tract, where trials focused on microbiological eradication measurements following single-dose regimens. For chronic conditions like COPD and bronchiectasis, evidence comes from long-term, placebo-controlled trials conducted over six months to a year. These studies monitored outcomes describing episodic or acute changes, primarily tracking the frequency of exacerbations.

Across all indications, research does not determine whether an individual will respond similarly to the group patterns observed in studies. Data for certain groups remain insufficient, particularly individuals with multiple co-existing conditions. Scientific discussion indicates that long-term effects are not fully established regarding non-infectious risks, such as patterns related to hearing changes observed in some studies. Furthermore, the potential for promoting antibiotic resistance is a recognized scientific concern that may influence future efficacy.

Frequently Asked Questions (FAQ)

Common questions about Zentavion (FAQ)


Q: What should I do if I forget to take my Zentavion dose?

A: If a dose is missed, official guidance indicates the dose is typically taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the general recommendation is to skip the missed dose and resume the regular dosing schedule. Doses are not recommended to be doubled to compensate for a missed dose.


Q: Is it possible for Zentavion to interact with common over-the-counter pain relievers?

A: Official drug documents list specific interactions with certain classes of medicines. These documents generally do not report specific interactions with common over-the-counter (OTC) pain relievers such as non-steroidal anti-inflammatory drugs (NSAIDs) or acetaminophen.


Q: Can Zentavion cause long-term dependency or addiction?

A: According to official drug facts, Zentavion (Azithromycin) is not classified as a controlled substance by regulatory bodies. This indicates the medicine does not have the profile associated with long-term dependency or addiction.


Q: Is Zentavion safe to take with birth control pills?

A: Official product information states that the effectiveness of hormonal contraceptives (birth control pills) may be lessened during Zentavion treatment and for a period of 28 days following the last dose. Regulatory warnings indicate that patients may need to use an alternative, non-hormonal back-up method during treatment and for the following two months.


Q: Are there any specific foods or drinks to avoid while taking Zentavion?

A: Zentavion tablets and most standard suspensions can typically be taken with or without food. However, the extended-release form of the medicine must be taken on an empty stomach (one hour before or two hours after a meal). No other official dietary changes are usually required.


Q: What should I do if I experience a severe side effect from Zentavion?

A: If signs of a severe side effect are experienced, such as a severe rash, yellowing of the skin or eyes, or a fast or irregular heartbeat, the recommendation is to discontinue use immediately. Regulatory guidance notes that emergency medical treatment should be sought immediately.


Q: What is the recommended duration of treatment with Zentavion?

A: The required duration of treatment varies significantly based on the specific infection being addressed, as described in regulatory documents. Treatment courses can range from a single dose for some conditions to a multi-day course, or even longer for specific prevention regimens.


Q: Can Zentavion be used by children or teenagers?

A: Regulatory documents state that the safety and effectiveness for most uses are not established for infants under 6 months of age. For approved indications, use in children and teenagers (aged 6 months and older) is based on weight-calculated dosing. Some forms, like tablets, may be restricted for children weighing under 45 kg.


Q: What is the maximum amount of time Zentavion stays in the body?

A: Zentavion has a prolonged tissue half-life, which is the time it takes for half of the drug to be eliminated from the system. Due to this property, the drug can remain detectable in the body for an extended period, potentially up to 15 days or longer, according to pharmacokinetic information.


Q: Are there any known interactions between Zentavion and alcohol?

A: Official regulatory documents do not report a dangerous drug-alcohol interaction that reduces effectiveness. However, consuming alcohol may potentially worsen common side effects such as nausea, dizziness, or headache, which may interfere with recovery.


Q: Does Zentavion need to be taken at a specific time of day?

A: For most courses of Zentavion, the medicine is typically taken once daily. However, for the extended-release form, official instructions specify taking it on an empty stomach, either one hour before or two hours after a meal.


Q: Can Zentavion affect my blood pressure?

A: Official warnings primarily focus on the risk of QT interval prolongation, which is an effect on heart rhythm. Direct effects on blood pressure are not explicitly listed among the serious adverse reaction warnings in official prescribing information.


Q: Do I need to change my diet while taking Zentavion?

A: Unless a healthcare provider gives specific instructions, individuals are advised to maintain their usual diet while taking Zentavion. The main nutritional concern is avoiding antacids near the dose time.


Q: Does Zentavion affect my ability to drive or operate machinery?

A: Official patient information generally states that Zentavion is not expected to affect the ability to drive or operate complex machinery. However, if uncommon side effects like dizziness or vertigo occur, caution is indicated.


Q: Is there a generic version of Zentavion available?

A: Yes, the active ingredient in Zentavion, which is Azithromycin, is a widely used and available medication. It is commonly accessible as a generic equivalent.


Q: Is Zentavion safe during pregnancy?

A: Official guidance states that use during pregnancy is permitted only if the benefit is determined to outweigh the potential risk. This assessment is based on the clinical need, as described in regulatory documentation.


Q: What happens if I stop taking Zentavion suddenly?

A: Regulatory guidelines emphasize that the medicine is intended to be taken for the full treatment time as prescribed, even if symptoms improve sooner. This helps to ensure the infection is fully cleared and to limit the potential for the development of antibiotic resistance.


Q: Are there lifestyle changes that help Zentavion work better?

A: The medicine's action is not dependent on specific lifestyle changes. However, health professionals often recommend maintaining adequate hydration and getting proper rest while recovering from an infection, as these practices support the body's natural immune response.


Q: What are the signs of an allergic reaction to Zentavion?

A: Signs of a serious allergic reaction may include swelling of the face, throat, or lips; hives or severe rash; difficulty breathing or swallowing; or severe dizziness/fainting. These are listed in official documents as reasons to seek immediate medical attention.


Q: Can Zentavion affect my sleep patterns?

A: Official side effect classifications list dizziness and vertigo as uncommon effects, which might indirectly influence the quality of sleep. Fatigue or tiredness is also uncommonly reported, but the drug is not classified as a direct sleep pattern disruptor.


Q: Is Zentavion a controlled substance?

A: No, Zentavion (Azithromycin) is a prescription medicine but it is not classified as a controlled substance by US regulatory agencies.


Q: What should I tell my dentist before a procedure if I'm taking Zentavion?

A: General regulatory guidelines advise informing all healthcare providers, including dentists, about all medications being used. This allows them to consider any potential issues or interactions with other drugs they may use or prescribe.


Q: Is it okay to take Zentavion with my morning coffee?

A: Zentavion tablets and standard suspensions can generally be taken with or without food or beverages. However, it is important to check if a beverage contains antacids, as products containing aluminum or magnesium hydroxide must be separated from the dose by at least two hours.


Q: Does Zentavion interact with multivitamins?

A: Official interaction lists typically specify interactions with prescription drugs, herbal products, and certain antacids. They do not usually report specific interactions between Zentavion and standard daily multivitamins.


Q: Why do doctors prescribe Zentavion for different conditions?

A: Zentavion is officially categorized as an anti-infective agent because its active ingredient (Azithromycin) has a broad spectrum of activity. This means it can target and combat different types of susceptible bacteria, making it useful for a variety of approved infections like those in the respiratory tract or skin.


Q: Does Zentavion make you tired or drowsy?

A: Official prescribing information notes that fatigue or tiredness is an uncommon side effect reported in clinical trials, occurring in less than 1% of patients. Uncommon effects also include dizziness and vertigo.


Q: What do I do if I accidentally take two Zentavion doses?

A: Official guidelines note that in the event of a suspected overdose or if more than the prescribed amount is taken, calling the poison control helpline or seeking emergency medical help is recommended.


Q: Can Zentavion affect the results of lab tests?

A: The concentration of Zentavion in the body can be monitored, which is relevant to certain clinical tests. As with any medication, official guidelines recommend informing laboratory personnel about all medicines being taken, as this information may be relevant to interpreting test results.


Q: Is there an age limit for taking Zentavion?

A: The safety of Zentavion is not established for most uses in infants under 6 months of age. There is no upper age limit, though caution is specifically advised for older adults due to a potentially higher susceptibility to certain cardiac arrhythmias.


Q: How long after stopping Zentavion are drug interactions a concern?

A: Due to its prolonged tissue half-life, Zentavion remains in the body for an extended time. The potential for certain drug interactions may extend beyond the treatment period. Specific warnings for hormonal contraceptives, for example, extend for 28 days following the last dose.


Q: Is Zentavion available as a chewable or liquid formulation?

A: The medicine is available in several forms, including oral tablets and a powder for oral suspension (which creates a liquid form). Official documents typically do not specify a separate 'chewable' tablet formulation.


Q: Do certain medical conditions make Zentavion unsafe to use?

A: Yes, official eligibility rules detail conditions where use is contraindicated (prohibited), such as a known allergy to the drug or a history of liver problems associated with its prior use. It also requires caution in patients with severe kidney or liver issues, heart rhythm disorders, or myasthenia gravis.


Q: Can Zentavion be split, crushed, or chewed?

A: The hard capsule formulation used for the anti-nausea regimen must be swallowed whole and should not be split, crushed, or chewed. For other forms, consulting with a healthcare professional or pharmacist for specific guidance is generally recommended.


Q: Is Zentavion safe for people with a history of heart issues?

A: Official warnings specifically highlight a risk of QT interval prolongation and the potential for cardiac arrhythmias (abnormal heart rhythms). Use requires caution in patients with a history of heart rhythm issues or other proarrhythmic conditions.


Q: Why is Zentavion sometimes described as 'novel'?

A: Zentavion is formally classified as an azalide antibiotic, a subclass of macrolides. This classification is due to a unique structural modification—the addition of a nitrogen atom in the chemical ring—that sets it apart from older macrolides like Erythromycin.

How should Zentavion be stored and disposed of?

How to Store and Dispose of Zentavion?

Zentavion (Azithromycin) must be stored and handled according to the following official requirements.


Storage and Stability

Product Form Storage Temperature/Condition
Dry Powder/Tablets Store at Controlled Room Temperature: 20 C to 25 C (68 F to 77 F).
Reconstituted Suspension Store at room temperature (up to 30 C) or refrigerate (5 C). Do not freeze.

The medicine must be kept in its original, tightly closed container and stored away from excess heat and moisture. The liquid suspension has a strict discard limit of 10 days after it is mixed with water. For child safety, the product must be stored out of the reach and sight of children.


Disposal Requirements

Unused, expired, or leftover Zentavion should be disposed of using a drug take-back program or mail-back disposal program. If these are unavailable, the medicine must be mixed with an undesirable substance (like coffee grounds or dirt), placed in a sealed bag, and thrown into the household trash, in accordance with regulatory guidelines. Do not flush the medication down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zentavion found in:

A-Z Index: